{"name":"Hanlim Pharm. Co., Ltd.","slug":"hanlim-pharm-co-ltd","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":11,"colorKey":"immunology","drugs":[{"name":"HL140 10/10","genericName":"HL140 10/10","slug":"hl140-10-10","indication":"Other","status":"phase_3"},{"name":"HL151","genericName":"HL151","slug":"hl151","indication":"Other","status":"phase_3"},{"name":"HL301","genericName":"HL301","slug":"hl301","indication":"Other","status":"phase_2"},{"name":"Venitol Tab.","genericName":"Venitol Tab.","slug":"venitol-tab","indication":"Chronic venous insufficiency","status":"marketed"},{"name":"HL140 20/10","genericName":"HL140 20/10","slug":"hl140-20-10","indication":"Other","status":"phase_3"},{"name":"HL237 tablet","genericName":"HL237 tablet","slug":"hl237-tablet","indication":"Other","status":"phase_2"},{"name":"Placebo of Venitol Tab.","genericName":"Placebo of Venitol Tab.","slug":"placebo-of-venitol-tab","indication":"Other","status":"marketed"},{"name":"Placebo(for Risedronate)","genericName":"Placebo(for Risedronate)","slug":"placebo-for-risedronate","indication":"Osteoporosis prevention in postmenopausal women","status":"phase_3"},{"name":"Risedronate/Cholecalciferol combination","genericName":"Risedronate/Cholecalciferol combination","slug":"risedronate-cholecalciferol-combination","indication":"Osteoporosis in postmenopausal women","status":"marketed"},{"name":"mometasone furoate plus azelastine HCl","genericName":"mometasone furoate plus azelastine HCl","slug":"mometasone-furoate-plus-azelastine-hcl","indication":"Allergic conjunctivitis","status":"phase_3"},{"name":"risedronate combine","genericName":"risedronate combine","slug":"risedronate-combine","indication":"Treatment of osteoporosis in postmenopausal women","status":"phase_3"}]},{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"oncology","drugs":[{"name":"Active comparator2 : Telmisartan","genericName":"Active comparator2 : Telmisartan","slug":"active-comparator2-telmisartan","indication":"Hypertension","status":"phase_3"},{"name":"Active comparator1 : Ezetimibe / Rosuvastatin","genericName":"Active comparator1 : Ezetimibe / Rosuvastatin","slug":"active-comparator1-ezetimibe-rosuvastatin","indication":"Hypercholesterolemia and dyslipidemia for cardiovascular risk reduction","status":"phase_3"},{"name":"Experimental : Ezetimibe / Rosuvastatin + Telmisartan","genericName":"Experimental : Ezetimibe / Rosuvastatin + Telmisartan","slug":"experimental-ezetimibe-rosuvastatin-telmisartan","indication":"Hypercholesterolemia and hypertension in patients requiring combination therapy","status":"phase_3"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"neuroscience","drugs":[{"name":"HL140 5/10","genericName":"HL140 5/10","slug":"hl140-5-10","indication":"Non-small cell lung cancer, PD-L1 positive","status":"phase_3"},{"name":"HL301(Experimental)","genericName":"HL301(Experimental)","slug":"hl301-experimental","indication":"Metastatic non-small cell lung cancer, PD-L1 positive","status":"phase_3"}]},{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"infectious","drugs":[{"name":"Talion Tab","genericName":"Talion Tab","slug":"talion-tab","indication":"Type 2 diabetes","status":"phase_3"},{"name":"Umkamin(Active Comparator)","genericName":"Umkamin(Active Comparator)","slug":"umkamin-active-comparator","indication":"Type 2 diabetes","status":"phase_3"}]},{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"cardiovascular","drugs":[{"name":"Charcotrace Inj.","genericName":"Charcotrace Inj.","slug":"charcotrace-inj","indication":"Diagnostic imaging of neurological lesions and neural pathways","status":"phase_3"}]}],"pipeline":[{"name":"Active comparator2 : Telmisartan","genericName":"Active comparator2 : Telmisartan","slug":"active-comparator2-telmisartan","phase":"phase_3","mechanism":"Telmisartan blocks angiotensin II type 1 (AT1) receptors, preventing vasoconstriction and reducing blood pressure.","indications":["Hypertension","Cardiovascular risk reduction in patients with hypertension"],"catalyst":""},{"name":"HL140 10/10","genericName":"HL140 10/10","slug":"hl140-10-10","phase":"phase_3","mechanism":"HL140 10/10 is an investigational drug with an undisclosed mechanism of action.","indications":[],"catalyst":""},{"name":"HL151","genericName":"HL151","slug":"hl151","phase":"phase_3","mechanism":"HL151 is an investigational therapeutic agent in phase 3 development by Hanlim Pharm, with mechanism details not publicly disclosed.","indications":[],"catalyst":""},{"name":"HL301","genericName":"HL301","slug":"hl301","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Venitol Tab.","genericName":"Venitol Tab.","slug":"venitol-tab","phase":"marketed","mechanism":"Venitol is a venotropic agent that improves venous tone and microcirculation by enhancing vascular endothelial function.","indications":["Chronic venous insufficiency","Varicose veins","Hemorrhoids"],"catalyst":""},{"name":"Active comparator1 : Ezetimibe / Rosuvastatin","genericName":"Active comparator1 : Ezetimibe / Rosuvastatin","slug":"active-comparator1-ezetimibe-rosuvastatin","phase":"phase_3","mechanism":"This combination reduces LDL cholesterol through dual inhibition of cholesterol absorption (ezetimibe) and hepatic cholesterol synthesis (rosuvastatin).","indications":["Hypercholesterolemia and dyslipidemia for cardiovascular risk reduction"],"catalyst":""},{"name":"Charcotrace Inj.","genericName":"Charcotrace Inj.","slug":"charcotrace-inj","phase":"phase_3","mechanism":"Charcotrace is a diagnostic imaging agent used to visualize and trace neural pathways and lesions in the central and peripheral nervous system.","indications":["Diagnostic imaging of neurological lesions and neural pathways"],"catalyst":""},{"name":"Experimental : Ezetimibe / Rosuvastatin + Telmisartan","genericName":"Experimental : Ezetimibe / Rosuvastatin + Telmisartan","slug":"experimental-ezetimibe-rosuvastatin-telmisartan","phase":"phase_3","mechanism":"This combination reduces cholesterol and blood pressure by inhibiting intestinal cholesterol absorption and HMG-CoA reductase while blocking angiotensin II receptors.","indications":["Hypercholesterolemia and hypertension in patients requiring combination therapy","Cardiovascular risk reduction in dyslipidemic hypertensive patients"],"catalyst":""},{"name":"HL140 20/10","genericName":"HL140 20/10","slug":"hl140-20-10","phase":"phase_3","mechanism":"HL140 20/10 is a fixed-dose combination product from Hanlim Pharm that combines two active pharmaceutical ingredients in a 20/10 mg ratio.","indications":[],"catalyst":""},{"name":"HL140 5/10","genericName":"HL140 5/10","slug":"hl140-5-10","phase":"phase_3","mechanism":"HL140 5/10 is a small molecule that targets the PD-1/PD-L1 pathway.","indications":["Non-small cell lung cancer, PD-L1 positive"],"catalyst":""},{"name":"HL237 tablet","genericName":"HL237 tablet","slug":"hl237-tablet","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"HL301(Experimental)","genericName":"HL301(Experimental)","slug":"hl301-experimental","phase":"phase_3","mechanism":"HL301 is an experimental drug that targets the PD-1/PD-L1 pathway to enhance anti-tumor immune response.","indications":["Metastatic non-small cell lung cancer, PD-L1 positive","Melanoma"],"catalyst":""},{"name":"Placebo of Venitol Tab.","genericName":"Placebo of Venitol Tab.","slug":"placebo-of-venitol-tab","phase":"marketed","mechanism":"This is a placebo formulation with no active pharmacological mechanism.","indications":[],"catalyst":""},{"name":"Placebo(for Risedronate)","genericName":"Placebo(for Risedronate)","slug":"placebo-for-risedronate","phase":"phase_3","mechanism":"Placebo does not have a known mechanism of action as it is an inactive substance.","indications":["Osteoporosis prevention in postmenopausal women"],"catalyst":""},{"name":"Risedronate/Cholecalciferol combination","genericName":"Risedronate/Cholecalciferol combination","slug":"risedronate-cholecalciferol-combination","phase":"marketed","mechanism":"Risedronate inhibits bone resorption by blocking osteoclast activity, while cholecalciferol (vitamin D3) enhances calcium absorption and supports bone mineralization.","indications":["Osteoporosis in postmenopausal women","Osteoporosis in men","Glucocorticoid-induced osteoporosis"],"catalyst":""},{"name":"Talion Tab","genericName":"Talion Tab","slug":"talion-tab","phase":"phase_3","mechanism":"Talion Tab is a small molecule that inhibits the activity of a specific enzyme.","indications":["Type 2 diabetes"],"catalyst":""},{"name":"Umkamin(Active Comparator)","genericName":"Umkamin(Active Comparator)","slug":"umkamin-active-comparator","phase":"phase_3","mechanism":"Umkamin is a glucagon-like peptide-1 (GLP-1) receptor agonist.","indications":["Type 2 diabetes"],"catalyst":""},{"name":"mometasone furoate plus azelastine HCl","genericName":"mometasone furoate plus azelastine HCl","slug":"mometasone-furoate-plus-azelastine-hcl","phase":"phase_3","mechanism":"Mometasone furoate is a corticosteroid that reduces inflammation, while azelastine HCl is an antihistamine that blocks histamine receptors.","indications":["Allergic conjunctivitis"],"catalyst":""},{"name":"risedronate combine","genericName":"risedronate combine","slug":"risedronate-combine","phase":"phase_3","mechanism":"Risedronate combines with other medications to inhibit bone resorption by acting on osteoclasts.","indications":["Treatment of osteoporosis in postmenopausal women"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiigFBVV95cUxQRTV2cHFhZm5BYlRoM3I2WVNfb2kxWEhNbllDTmhiSF9Lbm9BNXYweGVsaXdEcmVMZXlTam56TG42ZUFBUWlQMk9XY2UwVGdVM2dVcWFscVlFUlpMcEFrdDZLSS05RVNNS1BLZDhhTm5CanN0cHhnSXZYemN3OEVPODRVTmtRR0JqNHc?oc=5","date":"2026-01-01","type":"pipeline","source":"Investing News Network","summary":"Inside the ASX Biotech Boom: What’s Fuelling the Next Wave - Investing News Network","headline":"Inside the ASX Biotech Boom: What’s Fuelling the Next Wave","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi7wFBVV95cUxQOGVxNUxrc2RWWFNoc3RIQmR2RFU3NHRuYnZnU3RVdnRGQkx4YjdQcDY1Wm92cmNwQnNPbEtlNWRRMmVRVkl2aGNFWTU5c3oxTC01Y2VfeS1NY3AtSFhQNk9fODJ2SUtBUUw3SVJyWHp4b0RhaVJHY1h3SU9iNVFuMHRqUHk4TXpCcWFYOEFIZWVUWVo2V296OW13V3lzajlQUTB1cktzdzRabG1IbEtzRDBHc1ZkRlU1ODM3NUVnWlY1a2dReldSWXdoMGk1TkwxNkk0WEJ4WkJvN1o0QUNoNng1ZjZGaVpHcVhlLWdDVQ?oc=5","date":"2025-12-22","type":"trial","source":"smallcaps.com.au","summary":"Korean partner backs Invion’s INV043 ahead of Australia first-in-human trial - smallcaps.com.au","headline":"Korean partner backs Invion’s INV043 ahead of Australia first-in-human trial","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxNb1BLb3dNSUtBaTZicjNiaTByT09iM3VoNVRyelFtazNsck9xQUxTOVh1TG0tU3JIOUlZdDZ0TUZhS2RBdWNqQUFPYm42Ni11TTd3NFhQRVdLeC1DUU9YX3BmaTd4cDVneTVXd3JzdXF5OUxsZ1pxbXRhR0tsempZeGtkNFhhT0tFQVY4bjlrX3Y4akljOENOZnZyTkowRERvbnc4U2djRGk?oc=5","date":"2025-04-14","type":"pipeline","source":"Investing News Network","summary":"Invion: Revolutionizing Photodynamic Therapy (PDT) for Cancer, Infectious Diseases - Investing News Network","headline":"Invion: Revolutionizing Photodynamic Therapy (PDT) for Cancer, Infectious Diseases","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilAJBVV95cUxOSERqOXo3RmVqLWUzVzZROGdjeDdMWUJFRDFndFFuUEVKZVB1ZUFyN0trS3Q2ZkJZVC1BamQtdTBHYzlacGRqVTZIMC1tX04zc1NXV21URmlNSHlPMjMwYkozMHdacFVsNnljVURabG43YWo0bGdOSUlaNmVpZGVYWk5zZzREUDVSNFNaVVBodnQtSEdBLWRBRUNUM2ZzUldVUl85cGw2S0daYk9oLUFUQXFqdWJmdGh0d1JkTzh3anZORm5wMk5oZU55ZE5PN2FWYnBiQThGUW9waE10amtuSXMyQkYzaTdvckl3dHVQUERITlJzVmxKMnpNSDB4M1lpZ212cWQ1T3JVR2l6YVo1U3lLS3I?oc=5","date":"2025-03-04","type":"regulatory","source":"PR Newswire","summary":"Ono's ROMVIMZA Approval Shakes Up Tenosynovial Giant Cell Tumors Market, Challenging Daiichi Sankyo's TURALIO Dominance | DelveInsight - PR Newswire","headline":"Ono's ROMVIMZA Approval Shakes Up Tenosynovial Giant Cell Tumors Market, Challenging Daiichi Sankyo's TURALIO Dominance ","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTFBkN29EMzZLV1l4RHBmNUg3X1VTclI5cERqZkJBeW9FSEpVbnZJZFhzOTBpdDhXTDgxNHppMUlWWDFyV01pQkM0S3BVSlZDTVZ4blYybHAzVWo1VzdabFRfU0thM3RQNkM0eGI5ZXFB0gFyQVVfeXFMTmJTNGFVeFkwMEhXaENUNzNBbW9TTGJnNEpRWWxaREZkT3dIanVha2JQSWtSWGxRN1JQYUZFT2ZXNGZCYU9lLUhOS05BQUZldEl3ZmFULUQ2UFhFS2VaNlpWaGkwZkVvb3hyQmNYS0FKLUdB?oc=5","date":"2024-05-20","type":"pipeline","source":"koreabiomed.com","summary":"Hanlim Pharm to advance into global market with allergic rhinitis suppression spray - koreabiomed.com","headline":"Hanlim Pharm to advance into global market with allergic rhinitis suppression spray","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiAJBVV95cUxPYXFwZ3BwV3JmVkVSakFUUnpaQVhFcFdseXlEY3RIUUdTMFVlaC1HR0RuQkhYSDYzQW1UcGU3R2pHOGZOUHhKUjdtQ3FPQzcwY1VVLWJPOUFjZUdkS3FVSExlRUJmdlNaZHJTNDB1bktlMHVwQ04xdnoxQTI5WWg2MnJ1UmZ5NGUxMnVqbS13dzdKdUZ5RlZNS2xoWVVRWmpPRTBpbUZLMF9SVVFXYWRJeXlZYkRqd2NBXzV0OE9wU1p4YXM1enVtbl9zRElqQjhpX0swUldGcy0xTlRXbU5lbG9HeXhreEg3elllYW1Hc2RSY3pTU3ZWWEVIYWE1NV90Uld3X05vbXQ?oc=5","date":"2022-07-26","type":"pipeline","source":"PR Newswire","summary":"New Therapeutics Options in Rheumatoid Arthritis Pipeline as 120+ Key Companies are Working on Drug Profiles | DelveInsight - PR Newswire","headline":"New Therapeutics Options in Rheumatoid Arthritis Pipeline as 120+ Key Companies are Working on Drug Profiles | DelveInsi","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMia0FVX3lxTE4wMF9XZ0NOMW5FRHp0UlV0V3p2bDN1Tm1NZm1Hcnd4a2hYNVN2RWg4WnlSNlBNSk5FYkhFdjJzUFM5bG8zeUtfeGIzQmZBYUsyVkozTEkzQThDZHlnSTQtc24zZWIzQlZOeFNJ0gFvQVVfeXFMT3RveFZRRlNNTXZOYnRZa1dQeDVBT0NjbzNTYl9lLXpQOHVraW00VXBXclYySTJoOUlTTmx1d2NHbXNxZklSYXRWVmg3UE5nZVYwMm5mOWpPSjZLVnBVdkZCb0NGMEZKbU5hT0tYY3Bn?oc=5","date":"2017-07-06","type":"patent","source":"koreabiomed.com","summary":"Will patent lawsuit results affect market of Lyrica Capsule? - koreabiomed.com","headline":"Will patent lawsuit results affect market of Lyrica Capsule?","sentiment":"neutral"}],"patents":[],"drugCount":19,"phaseCounts":{"phase_3":14,"phase_2":2,"marketed":3},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}